title: Exploring the potential of adjunct therapy in tuberculosis.
abstract: A critical unmet need for treatment of drug-resistant tuberculosis (TB) is to find novel therapies that are efficacious, safe, and shorten the duration of treatment. Drug discovery approaches for TB primarily target essential genes of the pathogen Mycobacterium tuberculosis (Mtb) but novel strategies such as host-directed therapies and nonmicrobicidal targets are necessary to bring about a paradigm shift in treatment. Drugs targeting the host pathways and nonmicrobicidal proteins can be used only in conjunction with existing drugs as adjunct therapies. Significantly, host-directed adjunct therapies have the potential to decrease duration of treatment, as they are less prone to drug resistance, target the immune responses, and act via novel mechanism of action. Recent advances in targeting host-pathogen interactions have implicated pathways such as eicosanoid regulation and angiogenesis. Furthermore, several approved drugs such as metformin and verapamil have been identified that appear suitable for repurposing for the treatment of TB. These findings and the challenges in the area of host- and/or pathogen-directed adjunct therapies and their implications for TB therapy are discussed.
authors.affiliation: CSIR-Open Source Drug Discovery (OSDD) Unit, Council for Scientific and Industrial Research, Anusandhan Bhavan, 2 Rafi Marg, New Delhi, India. Electronic address: gvrayasam@csir.res.in.
authors.forename: Geetha Vani
authors.initials: GV
authors.lastname: Rayasam
authors.affiliation: CSIR-OSDD Unit, SID, Indian Institute of Science, Bangalore, India.
authors.forename: Tanjore S
authors.initials: TS
authors.lastname: Balganesh
mesh_terms: D000818:Animals; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D054884:Host-Pathogen Interactions; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
keywords: efflux pump; host-directed adjunct therapies; repurposed drugs; virulence factors